| pubmed-article:16197652 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16197652 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16197652 | lifeskim:mentions | umls-concept:C0002871 | lld:lifeskim |
| pubmed-article:16197652 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:16197652 | lifeskim:mentions | umls-concept:C1518527 | lld:lifeskim |
| pubmed-article:16197652 | lifeskim:mentions | umls-concept:C1514923 | lld:lifeskim |
| pubmed-article:16197652 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:16197652 | pubmed:dateCreated | 2005-10-3 | lld:pubmed |
| pubmed-article:16197652 | pubmed:abstractText | Epoetin alfa (EPO) and darbepoetin alfa (DARB) are approved for the treatment of chemotherapy-related anemia (CRA) in patients with nonmyeloid malignancies. This study examined dosing and hematologic outcomes with these agents in community oncology clinics. | lld:pubmed |
| pubmed-article:16197652 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16197652 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16197652 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16197652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16197652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16197652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16197652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16197652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16197652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16197652 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16197652 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:16197652 | pubmed:issn | 0300-7995 | lld:pubmed |
| pubmed-article:16197652 | pubmed:author | pubmed-author:MarkTami LTL | lld:pubmed |
| pubmed-article:16197652 | pubmed:author | pubmed-author:FastenauJohnJ | lld:pubmed |
| pubmed-article:16197652 | pubmed:author | pubmed-author:PiechCatherin... | lld:pubmed |
| pubmed-article:16197652 | pubmed:author | pubmed-author:McKenzieR... | lld:pubmed |
| pubmed-article:16197652 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16197652 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:16197652 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16197652 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16197652 | pubmed:pagination | 1347-54 | lld:pubmed |
| pubmed-article:16197652 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:meshHeading | pubmed-meshheading:16197652... | lld:pubmed |
| pubmed-article:16197652 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16197652 | pubmed:articleTitle | Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. | lld:pubmed |
| pubmed-article:16197652 | pubmed:affiliation | Thomson Medstat, Washington, DC 20008, USA. tami.mark@thomson.com | lld:pubmed |
| pubmed-article:16197652 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16197652 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
